ATLANTA, GA – – (ACCESSWIRE – May 5, 2022) – – Holzer & Holzer, LLC is investigating whether HUTCHMED Limited (“HUTCHMED” or the “Company”) (NASDAQ: HCM) complied with federal securities laws. On May 2, 2022, HUTCHMED announced that the FDA issued a Complete Response Letter regarding its New Drug Application. According to HUTCHMED, the FDA determined that the Company’s current data package does not support approval in the U.S. and that a multi-regional clinical trial that includes subjects more representative of the U.S. patient population is required. Following this announcement, the Company’s stock price dropped. If you purchased HUTCHMED stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.